<DOC>
	<DOCNO>NCT00289835</DOCNO>
	<brief_summary>HYPOTHESIS 1 . Sealing moderate SVG lesion TAXUS stent prevents SVG atherosclerosis progression evaluate IVUS . 2 . Sealing moderate SVG lesion TAXUS stent accelerate SVG atherosclerosis angiographically non-diseased segment SVG evaluate IVUS . OBJECTIVES 1 . To determine effect stenting moderate SVG lesion paclitaxel-eluting stent comparison medical treatment limit SVG disease progression evaluate IVUS . 2 . To evaluate IVUS effect stenting moderate SVG lesion paclitaxel-eluting stent comparison medical treatment atherosclerosis progression angiographically non-diseased SVGs segment .</brief_summary>
	<brief_title>Treatment Moderate Vein Graft Lesions With Paclitaxel Drug Eluting Stents : The VELETI Trial</brief_title>
	<detailed_description>This prospective randomized study assess efficacy stenting moderate SVG lesion taxus stent prevention atherosclerosis progression SVGs evaluate IVUS . Patients previous coronary bypass surgery SVG implantation undergo coronary angiography clinical indication screen . If patient moderate lesion level SVGs includable study . After inclusion , patient randomize either stenting moderate SVG lesion taxus stent standard medical treatment . The use filter wire dilation strongly recommend . Following procedure , patient clinical control 1 month 6 month angiographic IVUS control study 1 year follow-up .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Written sign informed consent . Patients â‰¥18 year old . Clinical indication cardiac catheterization SVG angiography . Presence least one SVG lesion 30 % 70 % diameter stenosis visual estimation ( ) culprit lesion ( ) responsible clinical syndrome patient . Ejection fraction &lt; 20 % . Renal insufficiency creatinine &gt; 250 mg/dl . Presence 3 moderate SVG stenosis significant diffuse SVG disease . Unsuccessful angioplasty ( residual stenosis &gt; 30 % and/or TIMI flow &lt; 3 ) lesion treat procedure . Coronary angioplasty target SVG past . Cardiogenic shock . Remaining lesion ( ) treatment plan within follow year . Pregnancy . Contraindication aspirin and/or clopidogrel treatment . Allergy paclitaxel . Any disease limiting lifeexpectancy ( less 2 year ) . Definite presence high suspicion thrombus ulceration target lesion . Target lesion locate SVG culprit lesion ( present ) distance target lesion proximal distal part stent implant culprit lesion &lt; 4 cm . Vein graft diameter &lt; 2.5 mm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Coronary Artery Bypass Grafting</keyword>
	<keyword>Drug Eluting Stent</keyword>
	<keyword>Saphenous Vein Graft</keyword>
</DOC>